转自:Insight 数据库10 月 23 日,CDE 官网显示,翰森制药自主开发的RET 抑制剂HS-10365胶囊上市申请获受理,Insight 数据库推测适应症为RET 融合阳性非小细胞肺癌(NSCLC)。这是国内第 3 款报上市的国产 RET 抑制剂。来源:CDE 官网HS-10365 是一款高效、高选择性的酪氨酸激酶抑制剂。RET 基因是较为罕见的致癌基因,其编码 RET 蛋白(酪氨酸...
Source Link转自:Insight 数据库10 月 23 日,CDE 官网显示,翰森制药自主开发的RET 抑制剂HS-10365胶囊上市申请获受理,Insight 数据库推测适应症为RET 融合阳性非小细胞肺癌(NSCLC)。这是国内第 3 款报上市的国产 RET 抑制剂。来源:CDE 官网HS-10365 是一款高效、高选择性的酪氨酸激酶抑制剂。RET 基因是较为罕见的致癌基因,其编码 RET 蛋白(酪氨酸...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.